title: [Intravesical instillation of pirarubicin (THP) together with polyvinylpyrrolidone (PVP) in the prevention of postoperative recurrence of superficial bladder cancer].
abstract: OBJECTIVE
  Superficial bladder transitional cell carcinoma is aggressive and tends to recurrence after operation. In order to prevent the relapse of bladder neoplasms,this study was designed to explore the effect of intravesical instillation of pirarubicin (THP) together with polyvinylpyrrolidone (PVP) on patients with superficial bladder cancer who had undergone surgical operation.
  
  
  METHODS
  A total of 34 cases were enrolled from October 1999 to May 2002. After one week of operation, pirarubicin (20 mg) dissolved in 10 ml normal saline plus 20 ml PVP was instilled into bladder, and was retained for 60 minutes. In the following 7 weeks, intravesical instillation of pirarubicin was administered once a week. Subsequently it was done bi-monthly, finally once a month for 6 months.
  
  
  RESULTS
  Follow-up was performed for 5-26 months (mean:17.2 months). Among the 34 cases, recurrence was found in 2 cases (5.8%),bladder irritation in 6 cases (17.6%) and hematuria in 4 cases (11.7%) as well.
  
  
  CONCLUSIONS
  Intravesical instillation of THP/PVP is effective for prevention of postoperative recurrence of superficial bladder cancer with fewer side effects. Further study is needed for wide use in such way.
authors.affiliation: Department of Urology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, PR China. yuzhix@wz163.com
authors.forename: Zhi-Xian
authors.initials: ZX
authors.lastname: Yu
authors.forename: Zhi-Liang
authors.initials: ZL
authors.lastname: Weng
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Fang-Yi
authors.initials: FY
authors.lastname: Zhang
authors.forename: Xiao-Sa
authors.initials: XS
authors.lastname: Zhou
authors.forename: Cheng-Di
authors.initials: CD
authors.lastname: Li
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010592:Pharmaceutic Aids / Q000627:therapeutic use; D011184:Postoperative Period; D011205:Povidone / Q000627:therapeutic use*; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D010592:Pharmaceutic Aids; D004317:Doxorubicin; C027260:pirarubicin; D011205:Povidone